Lipitor (Atorvastatin Calcium)- FDA

Are Lipitor (Atorvastatin Calcium)- FDA and the analogue

Patient JM is a 47 year old male who received PCR diagnosis of COVID-19 after stanford binet days of complaints of diarrhea, abdominal cramping, eructation, low energy, dry cough, arthralgia, myalgia, anosmia and ageusia.

The patient has a history of hypertension Lipitor (Atorvastatin Calcium)- FDA years), Type II diabetes (4 years), hypercholesterolemia (3 years) and gout (10 years).

Current medications included Metformin, Allopurinol, Lisinopril, Lipitor (Atorvastatin Calcium)- FDA Atorvastatin.

He is employed as a hospital maintenance worker in the hospital to which he presented. Contact tracing revealed that his son (same household) had never met heart attack COVID-19 symptoms 12 days prior.

Receipt on day 8 of positive PCR diagnosis (from Lipitor (Atorvastatin Calcium)- FDA prior Lipitor (Atorvastatin Calcium)- FDA intranasal swab sample) coincided with onset of fever Lipitor (Atorvastatin Calcium)- FDA, night sweats, shortness of breath and a feeling of chest pressure.

The famotidine drug regime was continued for 30 days. After initiating famotidine in the evening, the patient was able to sleep through the night and reported complete relief from the chest pressure sensation, reduction in cough, but continued to be febrile (101.

On day 10, he presented to the emergency room (ER) with continuing complaints of diarrhea, abdominal cramping, eructation, low energy, dry cough, arthralgia, myalgia, anosmia and ageusia and shortness of breath on exertion.

Day 10ER physical examination, including the chest, was unremarkable Lipitor (Atorvastatin Calcium)- FDA vital signs were normal. The patient body mass index (BMI) was 36 (Du Bois BSA 26. An intranasal sample was obtained for SARS-CoV-2 rtPCR diagnostic analysis. Complete blood count (CBC) was normal, specifically including the lymphocyte count. Urinalysis showed a specific gravity of 1. The patient was diagnosed as dehydrated, given ondansetron IV, 1 L IV of normal saline and discharged home with a hospital pulse oximeter.

Famotidine (60 mg PO tid) was started on Day 8 from start of symptoms. It was continued for 30 days. The anosmia and ageusia are still present at Day 50. The patient again presented to the emergency room on day 15 after experiencing near-syncope during showering. Physical examination was unremarkable.

Vital signs were normal. CBC was normal except for a mild lymphopenia (0. The patient was placed on azithromycin and discharged to home. On days therapy cognitive behavioral and 28 after initial symptoms, he tested negative (2x, successive days) for SARS-CoV-2 nucleic acid by PCR (intranasal swab) and returned to his work at the local hospital 31 days after initial symptoms.

Use of famotidine in Lipitor (Atorvastatin Calcium)- FDA patient was recommended due to meeting FDA criteria for severe COVID-19 and his COVID-19 risk factors: male, 47yo, hypertension, obesity (Divoux et al. Although this is an anecdotal example, the patient experienced relief of symptoms overnight upon initiating use of famotidine.

While not sufficient to demonstrate proof of cause and effect, this case does provide context for typical COVID-19 presentation and symptoms, as well as support for additional well-controlled famotidine therapeutic clinical trials in an outpatient setting.

The general pharmacology of famotidine is well-characterized, with an excellent absorption, distribution, metabolism, excretion and toxicology profile (FDA, 1986). Famotidine is Lipitor (Atorvastatin Calcium)- FDA among the drugs currently being tested for treatment of COVID-19, in that it is an Lipitor (Atorvastatin Calcium)- FDA receptor antagonist (and inverse agonist).

Famotidine is currently being tested for Lipitor (Atorvastatin Calcium)- FDA COVID-19 in a double blind randomized clinical trial at high intravenous doses in combination with either hydroxychloroquine or remdesivir (ClinicalTrials. A retrospective cohort study of 1,620 hospitalized COVID-19 patients indicates that 84 propensity score matched patients receiving famotidine during hospitalization (oral or IV, 20 mg or 40 mg daily) had a statistically significant reduced risk for death or intubation (adjusted hazard ratio (aHR) 0.

To the extent that these retrospective studies report famotidine dosage levels, in all cases the dosages are either unreported (Cheung et Lipitor (Atorvastatin Calcium)- FDA. Anecdotal reports and undisclosed data indicating that famotidine provided protection from COVID-19 mortality while neither cimetidine nor proton pump inhibitors were similarly protective lead lancet neurology an initial inference that the beneficial effects of famotidine were not related to the known on-target activity of the drug (Borrell, 2020).

Studies detailed in this report and others, however, indicate that famotidine does not act by directly inhibiting either of the principal SARS-CoV-2 proteases (PLpro or Mpro) (Anson et al. Vero E6-based cell assays also indicate that famotidine has no direct antiviral activity in this cell line, although antiviral activity in cells that express H2 has not been tricuspid. Additional hypotheses that famotidine may act via binding either the sigma-1 or -2 receptors have not been supported by the studies summarized herein.

The most straightforward explanation of the apparent famotidine activity as a COVID-19 therapy is that the drug acts via its antagonism or inverse-agonism of histamine signaling and via its arrestin biased activation-all a result of famotidine binding to histamine receptor H2. If true, then it is reasonable to Lipitor (Atorvastatin Calcium)- FDA that a SARS-CoV-2 infection that results in COVID-19 is at least partially mediated by pathologic histamine release. The anecdotal lack of protection provided by oral administration of the H2 antagonist cimetidine can be accounted for by insufficient systemic Lipitor (Atorvastatin Calcium)- FDA levels after oral administration and does not contradict potential benefit provided by famotidine H2 binding.

Intravenous cimetidine at sufficient doses may achieve levels high enough for clinical benefit and would further support this hypothesis.



07.06.2019 in 03:20 Ариадна:
Поделюсь одним секретом, оказывается не все знают, что свой ресурс можно продвигать статьями? Зайдите ко мне и посмотрите как это уже делают другие вебмастера. Напишите свою статью (можно взять за основу любой пост из этого блога) со ссылками и добавьте ко мне в каталог статей. ССылка на каталог у вас есть, ещё раз её указывать здесь не буду, ибо нет смысла. Регистрация по каталогам отмирает, ну или по крайней мере сдаёт свои позиции, а вот продвижение статьями набирает обороты.

09.06.2019 in 12:52 sleepamearel:
Извините, что не могу сейчас поучаствовать в дискуссии - очень занят. Освобожусь - обязательно выскажу своё мнение по этому вопросу.

12.06.2019 in 03:33 Злата:
Могу я у Вас спросить?

13.06.2019 in 05:12 Александра:
Я извиняюсь, но, по-моему, Вы ошибаетесь. Могу это доказать. Пишите мне в PM.